Maxim downgraded Reviva Pharmaceuticals (RVPH) to Hold from Buy.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVPH:
- Why Is Vanguard Total Stock Market ETF (VTI) Falling Today, 4/7/2026?
- Reviva Pharmaceuticals price target lowered to $1 from $1.50 at Roth Capital
- Reviva Pharmaceuticals price target raised to $30 from $16 at Alliance Global
- RVPH Earnings this Week: How Will it Perform?
- Reviva Pharmaceuticals Announces $10 Million Equity Offering